BusinessActinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial ContinueBy Nasdaq OMXDec 27, 2017, 2:00 PM UTC
BusinessActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingBy Nasdaq OMXDec 12, 2017, 12:30 PM UTC
BusinessAileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology MeetingBy Nasdaq OMXDec 11, 2017, 9:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MBy Nasdaq OMXDec 11, 2017, 9:15 PM UTC
BusinessAptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual MeetingBy Nasdaq OMXDec 11, 2017, 9:04 PM UTC
BusinessOHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual MeetingBy Nasdaq OMXDec 11, 2017, 9:04 PM UTC
BusinessActinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 11:30 AM UTC
